Resveratrol post-treatment protects against neonatal brain injury after hypoxia-ischemia
Metrics: PDF 1260 views | HTML 1493 views | ?
Shulin Pan1,*, Songlin Li2,*, Yingying Hu1, Hao Zhang1, Yanlong Liu3, Huai Jiang1, Mingchu Fang1, Zhengmao Li3, Kebin Xu3, Hongyu Zhang3, Zhenlang Lin1, Jian Xiao3
1Department of Neonatology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325000, China
2The Institute of Life Sciences, Wenzhou University, Wenzhou 325035, China
3The School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China
*These authors contribute equally to this work
Jian Xiao, email: email@example.com
Zhenlang Lin, email: firstname.lastname@example.org
Keywords: resveratrol, hypoxia-ischemia, brain damage, inflammation, apoptosis
Received: July 25, 2016 Accepted: October 19, 2016 Published: November 02, 2016
Neonatal hypoxic-ischemic brain injury is a devastating disease with limited treatment options. Preventive treatment with resveratrol has indicated to be well tolerated and has lower toxicity in both experimental models and human patients. However, whether resveratrol administration post-hypoxic-ischemic protects against neonatal hypoxic-ischemic injury is not known. Here we reported that post-treatment with resveratrol significantly reduced brain damage at 7-day after the injury. We found that resveratrol reduced the expression levels of key inflammatory factors at the mRNA and protein levels, and at least partially via inhibiting microglia activation. Moreover, resveratrol exerted an anti-apoptotic effect, as assessed by TUNEL staining, and altered the expression of the apoptosis-related genes Bax, Bcl-2 and caspase3. Our data indicate that post-treatment with resveratrol protects against neonatal hypoxic-ischemic brain injury and suggest a promising therapeutic strategy to this disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.